Printer Friendly

Zoloft. (New & Approved).

(sertraline, Pfizer)

A selective serotonin reuptake inhibitor (SSRI) for treating premenstrual dysphoric disorder (PMDD), the second SSRI and second drug approved for this indication.

* Recommended Dosage: 50 mg/day throughout the menstrual cycle or during the luteal phase. If necessary, dose may be increased at 50-mg increments per cycle, up to 150 mg/day when taken throughout the cycle or 100 mg/day when taken during the luteal phase.

* Special Considerations: Effectiveness beyond 3 months has not been evaluated.

* Comment: Approval was based on two studies of Zoloft vs. placebo over three menstrual cycles. In a study of 251 patients, those who took Zoloft 50 mg/day during the first cycle, then 50-150 mg/day during later cycles, had significantly greater improvements, compared with placebo. In an intermittent dosing study of 281 patients, those on Zoloft 50 mg/day in the late luteal phase during the first cycle, and 50-100 mg/day in later cycles, also had significantly greater improvements.

See comments below in Sarafem section for clinician's perspective on both drugs.
COPYRIGHT 2002 International Medical News Group
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2002 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Author:Mechcatie, Elizabeth
Publication:OB GYN News
Date:Jul 15, 2002
Previous Article:Adverse reactions after approval in 10% of drugs. (FDA Standards Questioned).
Next Article:Sarafem. (New & Approved).

Related Articles
Pfizer Drug Zoloft(R) Receives FDA Approval For Treatment of Posttraumatic Stress Disorder.
/C O R R E C T I O N - Pfizer Inc (NYSE: PFE)/.
Pfizer Launches Web-Based Resource on Depression and Anxiety Disorders.
/C O R R E C T I O N -- Pfizer Inc (NYSE: PFE)/.
Zoloft. (New & Approved).
Zoloft(R) Receives FDA Approval for Treatment of Social Anxiety Disorder; First Selective Serotonin Reuptake Inhibitor Approved for Long-Term...

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters